Feasibility of the Motivational Interview based Adherence Therapy (MIAT) with Family Support Program to Promote Medication Adherence for Persons with Schizophrenia

Objective: To examine the feasibility of the Motivational Interview based Adherence Therapy (MIAT) with family support program. Method: This pilot study used purposive sampling to recruit 8 patients with schizophrenia and their major family caregivers. These patients received outpatient treatment at the Mental Health and Psychiatric Department, Abhakorn Kiattiwong Hospital, Sattahip Naval Base, Chon Buri province, Thailand. They were in adulthood (age 20 - 59 years), with diagnosis of schizophrenia disorder within 5 years, and with a previous history of re-hospitalization due to recurrent severe psychiatric symptoms from medication non-compliance. Instruments included demographic data record form, the Insight and Treatment Attitude Questionnaire, the Hogan Drug Attitude Inventory, the Medication Adherence Questionnaire, the MIAT with family support program, and a program evaluation questionnaire. Schizophrenic patients participated in 6 weekly sessions, 45 - 60 minutes per sessiom. Family caregiver for each patient participated in 3 rd and 6 th week. Three aspects of adherence were assessed at before and after 6 sessions, and 1 month follow-up after the last session. Descriptive statistics and repeated measures ANOVA were used to analyze the data. Results: Scores of insight into illness, adherence attitude, and adherence behavior at post-test and follow-up were significantly higher than the pre-test (P-value < 0 .05 for all). The participants and family caregivers were satisfied with the program’s activities. Suggestions were feasible to adjust the program. Conclusion: The Motivational Interview based Adherence Therapy (MIAT) with family support program was feasible for further studies with a larger sample size.

[1]  วัชรินทร์ วุฒิรณฤทธิ์ การส่งเสริมความร่วมมือในการรับประทานยาสำหรับผู้ป่วยจิตเภทในชุมชน PROMOTING MEDICATION ADHERENCE IN PERSONS WITH SCHIZOPHRENIA IN COMMUNITY , 2017 .

[2]  R. Gray,et al.  Is adherence therapy an effective adjunct treatment for patients with schizophrenia spectrum disorders? A systematic review and meta-analysis , 2016, BMC Psychiatry.

[3]  J. Thirthalli,et al.  Reasons for Schizophrenia Patients Remaining out of Treatment: Results from a Prospective Study in a Rural South Indian Community , 2016, Indian journal of psychological medicine.

[4]  E. Cheung,et al.  Adherence therapy versus routine psychiatric care for people with schizophrenia spectrum disorders: a randomised controlled trial , 2016, BMC Psychiatry.

[5]  E. Cheung,et al.  Effects of motivational interviewing-based adherence therapy for schizophrenia spectrum disorders: a randomized controlled trial , 2015, Trials.

[6]  S. Washizuka,et al.  The development and trial of a medication discontinuation program in the department of forensic psychiatry , 2015, Annals of General Psychiatry.

[7]  M. Semiz,et al.  Perspectives on reasons of medication nonadherence in psychiatric patients , 2015, Patient preference and adherence.

[8]  A. Outwater,et al.  Risk and protective factors for relapse among Individuals with Schizophrenia: A Qualitative Study in Dar es Salaam, Tanzania , 2014, BMC Psychiatry.

[9]  D. Linszen,et al.  The effect of motivational interviewing on medication adherence and hospitalization rates in nonadherent patients with multi-episode schizophrenia. , 2013, Schizophrenia bulletin.

[10]  W. Chien,et al.  The effectiveness of mutual support group intervention for Chinese families of people with schizophrenia: a randomised controlled trial with 24-month follow-up. , 2013, International journal of nursing studies.

[11]  W. Chien,et al.  Current approaches to treatments for schizophrenia spectrum disorders, part II: psychosocial interventions and patient-focused perspectives in psychiatric care , 2013, Neuropsychiatric disease and treatment.

[12]  Hui-Ching Wu,et al.  Quality of Life and Self-Stigma in Individuals with Schizophrenia , 2012, Psychiatric Quarterly.

[13]  D. Linszen,et al.  Interventions to improve adherence to antipsychotic medication in patients with schizophrenia–A review of the past decade , 2012, European Psychiatry.

[14]  P. Weiden,et al.  Measurement of psychiatric treatment adherence. , 2010, Journal of psychosomatic research.

[15]  J. Livingston,et al.  Correlates and consequences of internalized stigma for people living with mental illness: a systematic review and meta-analysis. , 2010, Social science & medicine.

[16]  K. Gournay,et al.  An RCT of adherence therapy for people with schizophrenia in Chiang Mai, Thailand. , 2007, Journal of clinical nursing.

[17]  A. L. Dal-Fabbro,et al.  Adherence to long term therapies: evidence for action , 2005 .

[18]  J. McEvoy,et al.  Insight in Schizophrenia. Its Relationship to Acute Psychopathology , 1989, The Journal of nervous and mental disease.

[19]  T. Hogan,et al.  A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity , 1983, Psychological Medicine.

[20]  P. El-Mallakh,et al.  UKnowledge UKnowledge , 2022 .

[21]  Mahendra Patel,et al.  Medicines adherence: Involving patients in decisions about prescribed medicines and supporting adherence , 2009 .